Search results
Rhône-Poulenc (French pronunciation: [ʁon pulɛ̃k]) was a French chemical and pharmaceutical company founded in 1928. In 1999, it merged with Hoechst AG to form Aventis . As of 2015, the pharmaceutical operations of Rhône-Poulenc are part of Sanofi and the chemicals divisions are part of Solvay group and Bayer Crop Science .
- 1928; 95 years ago
- Chemicals
- Étienne Poulenc
- merged with Hoechst AG
May 15, 2024 · Rhône-Poulenc SA, former French chemical manufacturer and leading producer of organic chemicals, synthetic fibres, and pharmaceuticals. It merged with Hoechst Aktiengesellschaft in 1999 to create the French-German pharmaceutical firm Aventis. The company originated as a dyestuffs manufacturer in 1801 under the name Maison Debai-Extraits ...
People also ask
Is Rhône-Poulenc a company?
What does Rhône-Poulenc do?
How much money did Rhône-Poulenc make in 1992?
What is Rh Ô NE Poulenc?
Rhône-Poulenc's business was dramatically internationalized through myriad acquisitions in the late 1980s and early 1990s. By the end of 1993, the company had operations in 140 countries and almost eighty percent of its income came from outside of France. Rhône-Poulenc traces its history to the formation of two separate companies established ...
Aug 15, 1993 · 15-08-1993 Print. French chemical and pharmaceuticals company Rhone-Poulenc has been transformed from a domestically- focused chemical group into a truly international life sciences group via 40 billion French francs ($6.7 billion) worth of acquisitions and around 75 disposals, say analysts Percy Lomax and John Doree at broker Robert Fleming ...
Rhône-Poulenc. Rhône-Poulenc was a French chemical and pharmaceutical company founded in 1928 through the merger of Société Chimique des Usines du Rhône and Établissements Poulenc Frères. In January 1999, Rhône-Poulenc merged with Hoechst AG to form Aventis. In 2004, Aventis went on to merge with Sanofi-Synthélabo forming Sanofi ...
May 29, 2018 · By 1992, 75 percent of Rh ô ne-Poulenc ’ s business was outside France, and the corporation had operations in 140 countries. Sales doubled from about $7.5 billion in 1986 to $15.4 billion in 1992. Rh ô ne-Poulenc ’ s U.S. sales increased from 11 percent of its 1987 total to 18.4 percent in 1993.
At the time of the merger, Rhône-Poulenc's business included the pharmaceutical businesses Rorer, Centeon (blood products), and Pasteur Merieux (vaccines), the plant and animal health businesses Rhône-Poulenc Agro, Rhône-Poulenc Animal Nutrition, and Merial, and a 67 percent share in Rhodia, a speciality chemicals company.
